5600-63-5

Basic information

• Product Name: 4-(4-nitrophenyl)butyryl chloride
• Synonyms: 4-(4-nitrophenyl)butyryl chloride;4-Nitrobenzenebutanoic acid chloride
• CAS NO: 5600-63-5
• Molecular Formula: C₁₀H₁₀ClNO₃
• Molecular Weight: 227.6443
• EINECS: 227-020-4
• Mol File: 5600-63-5.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 360.1°Cat760mmHg
• Flash Point: 171.6°C
• Appearance: /
• Density: 1.296g/cm³
• Vapor Pressure: 2.28E-05mmHg at 25°C
• Refractive Index: 1.556
• CAS DataBase Reference: 4-(4-nitrophenyl)butyryl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-nitrophenyl)butyryl chloride(5600-63-5)
• EPA Substance Registry System: 4-(4-nitrophenyl)butyryl chloride(5600-63-5)

Safety Data

• Hazardous Substances Data: 5600-63-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H10ClNO3/c11-10(13)3-1-2-8-4-6-9(7-5-8)12(14)15/h4-7H,1-3H2

Upstream product

• 79-37-8 oxalyl dichloride 
• 5600-62-4 4-(4-nitrophenyl)butanoic acid 

Downstream Products

• 143665-55-8 N-(3,4-Dimethoxy-benzyl)-N-methyl-4-(4-nitro-phenyl)-butyramide 
• 79195-81-6 N-n-Pentyl-4-(4-nitrophenyl)butylaminium chloride 
• 857760-44-2 C₁₀H₁₀N₂O₃ 
• 857760-44-2 C₁₀H₁₀N₂O₃ 
• 857760-44-2 5-(4-nitrophenyl)pyrrolidin-2-one 
• 914955-90-1 S-(+)-2β-{[4-(4'-nitrophenyl)butyryl]oxymethyl}-3α-[bis(4-fluorophenyl)methoxy]tropane 
• 427897-34-5 1-(4-Fluorophenyl)-4-(4-nitrophenyl)-butan-1-one 
• 93130-63-3 4-(4-Guanidino-phenyl)-butyric acid phenyl ester; compound with methanesulfonic acid 
• 93131-00-1 4-(4-Amino-phenyl)-butyric acid phenyl ester; hydrochloride 
• 143665-56-9 4-(4-Amino-phenyl)-N-(3,4-dimethoxy-benzyl)-N-methyl-butyramide 
• 143665-57-0 4-{4-[(3,4-Dimethoxy-benzyl)-methyl-amino]-butyl}-phenylamine 
• 218629-16-4 dimethyl 2,3-dihydro-5-<3-(4-nitrophenyl)propyl>-1H-pyrrolizine-6,7-dicarboxylate 
• 218629-17-5 dimethyl 2,3-dihydro-5-<3-(4-aminophenyl)propyl>-1H-pyrrolizine-6,7-dicarboxylate 

Relevant articles and documents

Ruthenium(II)-Catalyzed Enantioselective ?-Lactams Formation by Intramolecular C-H Amidation of 1,4,2-Dioxazol-5-Ones

We report the Ru-Catalyzed enantioselective annulation of 1,4,2-Dioxazol-5-Ones to furnish ?-Lactams in up to 97% yield and 98% ee via intramolecular carbonylnitrene C-H insertion. By employing chiral diphenylethylene diamine (dpen) as ligands bearing electron-Withdrawing arylsulfonyl substituents, the reactions occur with remarkable chemo- A nd enantioselectivities; the competing Curtius-Type rearrangement was largely suppressed. Enantioselective nitrene insertion to allylic/propargylic C-H bonds was also achieved with remarkable tolerance to the Ca?C and Ca‰iC bonds.

Non- C2-Symmetric Chiral-at-Ruthenium Catalyst for Highly Efficient Enantioselective Intramolecular C(sp3)-H Amidation

A new class of chiral ruthenium catalysts is introduced in which ruthenium is cyclometalated by two 7-methyl-1,7-phenanthrolinium heterocycles, resulting in chelating pyridylidene remote N-heterocyclic carbene ligands (rNHCs). The overall chirality results from a stereogenic metal center featuring either a or Δabsolute configuration. This work features the importance of the relative metal-centered stereochemistry. Only the non-C2-symmetric chiral-at-ruthenium complexes display unprecedented catalytic activity for the intramolecular C(sp3)-H amidation of 1,4,2-dioxazol-5-ones to provide chiral -lactams with up to 99:1 er and catalyst loadings down to 0.005 mol % (up to 11 ?200 TON), while the C2-symmetric diastereomer favors an undesired Curtius-type rearrangement. DFT calculations elucidate the origins of the superior C-H amidation reactivity displayed by the non-C2-symmetric catalysts compared to related C2-symmetric counterparts.

BENZTROPINE COMPOUNDS AND USES THEREOF

Disclosed are benztropine analogs having the formula (I) in which Ar is a C6-C20 monocyclic aryl group or a C10-C20 bicyclic aryl group or a heteroaryl, heterocyclic, or arylheterocyclic group having 2 to 12 carbon atoms and one or more heteroatoms selected from the group consisting of N, O, S, P, and any combination thereof; m = 1 to 5; n = 1 to 3; and R1 to R4 are as described in the specification; or a pharmaceutically acceptable salt or solvate thereof; pharmaceutical compositions and use thereof, e.g., in treating mental disorders.